AEOL-10150

DB05874ExperimentalSmall molecule

AEOL 10150 is developed by Aeolus as a therapeutic agents based on its proprietary small molecule catalytic antioxidants.

Mechanism: AEOL 10150 shows the ability to scavenge a broad range of reactive oxygen species, or free radicals. As a catalytic antioxidant, AEOL 10150 mimics and thereby amplifies the body's natural enzymatic systems for eliminating these damaging compounds. Because oxygen-derived free radicals are believed to have an important role in the pathogenesis of many diseases, aeolus' catalytic antioxidants are believed to have a broad range of potential therapeutic uses.
Curator reviewed
Primary indication: Investigated for use/treatment in amyotrophic lateral sclerosis (ALS).Curator reviewed
Formula / weight: C₄₈H₅₆Cl₉MnN₁₂ · 1175.05 g/mol (avg)
Code names: AEOL-10150

Resolves to

Compound

UNIIKPKO7W46E8CAS286475-30-7

Structure

InChIKeyXMYHQLIAYLLEKT-UHFFFAOYSA-ISMILES

[Cl-].[Cl-].[Cl-].[Cl-].[Cl-].[Mn+3].CCN1C=C[N+](CC)=C1\C1=C2/C=CC(=N2)\C(=C2/[N-]\C(\C=C2)=C(/C2=N/C(/C=C2)=C(\C2=CC=C1[N-]2)C1=[N+](CC)C=CN1CC)C1=[N+](CC)C=CN1CC)\C1=[N+](CC)C=CN1CC

Targets

P00441SOD1

What you can answer from here — as of March 06, 2025

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with AEOL-10150, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account